In January 2016, Mesoblast released results of a Phase2 clinical trial on 241 children with acute Graft-versus-host disease, that was not responsive to steroids,.
12.
In June 2015, Mesoblast received $ 5.8 million from the Australian Government for Research & Development ( R & D ) activities conducted during the 2014 financial year.
13.
In August 2014, Mesoblast announced in its 2014 results and corporate strategy that the Food and Drug Administration granted approval to advance to an MPC Phase 3 trial for chronic lower back pain.
14.
In May 2014, Mesoblast announced it would receive incentives from the Singapore Economic Development Board ( EDB ) for activities in Singapore related to manufacturing operations, as well as product development and commercialization.
15.
Granted US patent number 8, 858, 932 provides Mesoblast with exclusive commercial rights through to June 2029 . There is also potential for patent term and regulatory exclusivity extensions which would provide longer term protection.
16.
During the 2015 financial year, Mesoblast's licensee, JCR Pharmaceuticals Ltd, filed for regulatory approval for its GVHD MSC-based product, JR-031, in children and adults in Japan.
17.
On December 17, 2015, as part of the first quarter report, Mesoblast announced they anticipated patient enrollment completion for the first of two trials for phase 3 by third quarter, or mid-2016.
18.
On February 10, 2015, Mesoblast was granted a key patent by the United States Patent and Trademark Office ( USPTO ) covering its proprietary Mesenchymal Precursor Cell ( MPC ) technology for use in the treatment of degenerated intervertebral discs.
19.
During the conduct of the pediatric Phase 3 trial, Mesoblast expects to have discussions with the FDA regarding the trial design for a potential Phase 3 trial to support approval of this product for adults with steroid refractory liver or gut GVHD.
20.
In February 2016, Mesoblast's Licensee ( JCR Pharmaceuticals Co ., Ltd . ) sold its first allogeneic cell product TEMCELL?HS Inj ., for the treatment of acute graft versus host disease ( aGVHD ) in children and adults in Japan.
